ExploreWatchlistsPricing
  1. JP-listed companies
  2. RaQualia Pharma Inc.
  3. Financials
  4. Revenue

RaQualia Pharma Inc. (4579)

Market cap
¥22.3B
P/E ratio
-331.8x
Rakuoria Drug Discovery develops new pharmaceutical compounds through early-stage research and clinical trials, then licenses them to major pharmaceutical companies for revenue.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue (Million JPY)YoY (%)
Dec 31, 20253,980+28.07%
Dec 31, 20243,108+63.45%
Dec 31, 20231,901-34.85%
Dec 31, 20222,918+5.11%
Dec 31, 20212,776+150.72%
Dec 31, 20201,107-34.98%
Dec 31, 20191,703+128.74%
Dec 31, 2018745-47.54%
Dec 31, 20171,419+101.24%
Dec 31, 2016705+384.70%
Dec 31, 2015146-5.46%
Dec 31, 2014154-32.39%
Dec 31, 2013228+685.49%
Dec 31, 201229-95.76%
Dec 31, 2011684

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat